Table 3 Indication for biopsy and histology verified diagnosis in patients included in the NorKiBB biobank by sex and age, and for all 20 kidney biopsy centers in Norway in total
Sex | Age (years) | Total | ||||
|---|---|---|---|---|---|---|
Female | Male | < 50 | ≥ 50 | NorKiBB (2020-23) | Norway (2020-23) | |
Indications for biopsy (N) | 249 | 384 | 277 | 356 | 633 | 2395 |
Nephrotic syndrome | 29 (12%) | 58 (15%) | 33 (12%) | 54 (15%) | 87 (14%) | 438 (18%) |
Nephritic syndrome | 33 (13%) | 49 (13%) | 47 (17%) | 35 (10%) | 82 (13%) | 337 (14%) |
Acute kidney disease | 53 (21%) | 74 (19%) | 36 13%) | 91 (26%) | 127 (20%) | 704 (29%) |
Chronic kidney disease | 94 (38%) | 194 (51%) | 110 (40%) | 163 (46%) | 288 (45%) | 796 (33%) |
Isolated hematuria / Proteinuria | 40 (16%) | 9 (2%) | 51 (18%) | 13 (4%) | 49 (8%) | 120 (5%) |
Histologically verified diagnoses (N) | 234 | 358 | 255 | 337 | 592 | 2395 |
Minimal Change Disease | 11 (5%) | 13 (4%) | 9 (4%) | 15 (5%) | 24 (4%) | 114 (5%) |
Focal Segmental Glomerulosclerosis | 9 (4%) | 16 (5%) | 15 (6%) | 10 (3%) | 25 (4%) | 83 (3%) |
Membranous Glomerulonephritis | 9 (4%) | 17 (5%) | 8 (3%) | 18 (5%) | 26 (4%) | 98 (4%) |
Membranoproliferative | 4 (2%) | 3 (1%) | 2 (1%) | 5 (2%) | 7 (1%) | 38 (2%) |
Mesangioproliferative incl. IgA | 46 (20%) | 88 (25%) | 94 (37%) | 40 (12%) | 134 (23%) | 388 (16%) |
ANCA vasculitis | 15 (6%) | 23 (6%) | 9 (4%) | 29 (9%) | 38 (6%) | 143 (6%) |
Lupus nephritis | 17 (7%) | 8 (2%) | 19 (8%) | 6 (2%) | 25 (4%) | 76 (3%) |
Other glomerulonephritis | 5 (2%) | 10 (3%) | 3 (1%) | 12 (4%) | 15 (3%) | 121 (5%) |
Arterionephrosclerosis | 27 (12%) | 56 (16%) | 18 (7%) | 65 (19%) | 83 (14%) | 142 (6%) |
Diabetic nephropathy | 13 (6%) | 42 (12%) | 16 (6%) | 39 (12%) | 55 (9%) | 160 (7%) |
Tubulo-interstitial nephropathy | 22 (9%) | 32 (9%) | 18 (7%) | 36 (11%) | 54 (9%) | 176 (7%) |
Myeloma / light-chain disease | 12 (5%) | 6 (2%) | 7 (3%) | 11 (3%) | 18 (3%) | 19 (1%) |
Amyloidosis | 7 (3%) | 11 (3%) | 1 (0%) | 17 (5%) | 13 (2%) | 88 (4%) |
Alport’s | 4 (2%) | 5 (1%) | 7 (3%) | 2 (1%) | 9 (2%) | 12 (1%) |
Fabry’s | 3 (1%) | 3 (1%) | 0 (0%) | 6 (2%) | 6 (1%) | 18 (1%) |
Acute tubular necrosis | 5 (2%) | 8 (2%) | 5 (2%) | 8 (2%) | 13 (2%) | 79 (3%) |
Other non-GN kidney disease | 18 (8%) | 5 (1%) | 13 (5%) | 10 (3%) | 28 (5%) | 62 (3%) |
Normal | 7 (3%) | 12 (3%) | 11 (4%) | 8 (2%) | 19 (3%) | 56 (2%) |